Nonspecific hepatitis B surface antigen reactions with a third-generation enzyme immunoassay (Auszyme Monoclonal; Abbott Laboratories, North Chicago, IHl.) were investigated with 9,577 serum specimens in a clinical laboratory setting. Of the 196 serum specimens found reactive in Auszyme screen by the overnight procedure, 103 turned out to be true-positives, 71 were nonrepeatably reactive, and 22 were repeatably reactive but actually falsely positive (false-positive rate, 22 of 196, or 11.2%). Verification of the 196 screen reactives by the Auszyme 3-h incubation assay detected all but 4 true-positives, with a false-negative rate of 3.9% (4 of 103), and was negative for the rest. These observations reinforce the need for retesting all reactive specimens and confirming repeatedly reactive samples when the Auszyme Monoclonal test is used to detect hepatitis B surface antigen.
Enzyme immunoassay is the preferred method of most diagnostic laboratories for detecting hepatitis B virus seromarkers (3) . Although a number of manufacturers have been marketing hepatitis B enzyme immunoassay diagnostic kits, the products of Abbott Laboratories (North Chicago, Iii.) appear to have found wide acceptance in clinical laboratories. We became aware of nonspecific reactions with Auszyme Monoclonal, a qualitative third-generation hepatitis B surface antigen (HBsAg) enzyme immunoassay manufactured by Abbott Laboratories, and followed a verification protocol ( Fig. 1) to rule out the nonspecific reactivity. The manufacturer recognizes the potential for nonspecific Auszyme Monoclonal reactions, offers explanations, and recommends retesting all reactive specimens and confirming repeatedly reactive samples (Auszyme Monoclonal package insert). Recently, Skurrie and Garland, from Australia, reported false positivity with Auszyme Monoclonal and cautioned clinical laboratories on the potential mislabeling of HBsAg status when this test is used (6) . In this report, we present data gathered for a year to determine the extent of Auszyme Monoclonal nonspecific reactivity in a clinical laboratory setting.
Enzyme immunoassay technique was used to test for all hepatitis B virus seromarkers. The enzyme immunoassays kits were purchased from Abbott Laboratories, and the tests were carried out according to the instructions of the manufacturer by one experienced technologist.
All samples received for routine hepatitis B virus seroscreening or diagnosis were initially screened for HBsAg with Auszyme Monoclonal by the overnight procedure (incubation at room temperature for 16 h; procedure B), and the specimens were held at the ambient temperature until the results were read. All sera found screen reactive were retested by Auszyme Monoclonal procedure B and procedure A (incubation at 40°C for 3 h) within 24 h. Depending on the outcome, specimens were divided into three categories and analyzed further (Fig. 1) (Tables 1 these four instances, the Auszyme procedure B results were and 2). There were 22 serum specimens that were repeatably considered truly positive (Tables 1 and 2 ), thus increasing reactive by Auszyme procedure B but negative by procedure the true-positive total to 103. Conversely, the false-negative A and Ausria and negative for anti-HBc (Table 1 ). The pool rate for procedure A Auszyme was 3.9% (4 of 103). 3 samples gave optical density readings mostly in the range The assays of HBsAg proficiency panels gave accurate of about 0.200 to 0.700 (Tables 1 and 2 ). In this batch, and consistent readings in all instances except one: a sample subsequent follow-up samples tested negative for HBsAg by containing 0.1 U of ay subtype tested negative by Auszyme Auszyme procedure B, remained negative for anti-HBc and procedure A but positive by procedure B, indicating a higher anti-HBc immunoglobulin M, and continued to test negative sensitivity of the overnight incubation procedure. The lowby Auszyme procedure A and Ausria. None of these 22 est level of subtype ad measured was 0.1 U and was detected samples were from previously known HBsAg carriers or by both procedures. from those with a history of hepatitis. Therefore, these 22 Besides the overnight and 3-h Auszyme Monoclonal prowere considered falsely positive by the Auszyme procedure cedures, the manufacturer also recommends two other pro-B screen (false-positive rate, 22 of 196, or 11.2%). Finally, cedures for Auszyme, a 75-min incubation assay (procedure four serum samples tested repeatably reactive by Auszyme C) and a 2-h-1-h incubation assay (procedure D) specifically procedure B, negative by procedure A and Ausria, but for samples containing sodium azide. We did not use these positive for anti-HBc. Two of these were from a couple procedures in our study and do not know how they might previously known to be HBsAg carriers, and the others were compare with the two procedures we investigated. from two persons, both of whom had a history of hepatitis.
The results of our study indicate that the following prac- tical points may be worth considering when the Auszyme Monoclonal test is used to detect HBsAg. (i) The overnight Auszyme Monoclonal assay (procedure B) is overly sensitive and can give rise to false-positive reactions. In our study, the overall false-positive rate was 0.2% (22 of 9,577), similar to that (0.3%) reported by Skurrie and Garland (6) , but it rose to 11.2% when expressed in terms of the total Auszyme screen reactives (22 of 196). However, the Auszyme procedure B has a presumed negative predictive value of 100%, and therefore it is ideally suited as a screen test.
(ii) The nonrepeatably reactive results could well be due to technical errors (Ausyzme package insert); this is usually corrected by repeated testing. Also, the nonspecific reactions appear to be lost upon storage. Thus, repeated testing after a brief storage might be helpful to a great extent in overcoming the Auszyme Monoclonal false positivity. (iii) The 3-h incubation Auszyme Monoclonal assay (procedure A) is more specific in detecting HBsAg than the overnight procedure, and therefore it is ideally suited as a verification procedure for the overnight screen reactives. However, the 3-h incubation assay is less sensitive than the overnight procedure, with a false-negative rate of about 4%. When used as a supplementary test to HBsAg assay, the anti-HBc test had 100% positive and negative predictive values. Thus, in our limited series, anti-HBc was a reliable adjunct to HBsAg testing and helpful in detecting false Auszyme reactions. However, it is common knowledge that early in the acute stage of hepatitis B virus infection, tests for anti-HBc may be negative, and this negative rate could be as high as 8% (4). Therefore, negative anti-HBc tests cannot be entirely relied upon without a follow-up specimen tested subsequently for HBsAg and anti-HBc. Nevertheless, the maximum false-negative rate after both Auszyme procedure A and anti-HBc tests are used to verify the Auszyme procedure B screen reactives is expected to be the product of the individual false-negative rates, i.e., 4% x 8% = 0.32%, an extremely lower rate. Also in this context, the occurrence of a variant of hepatitis B virus (1, 2, 5, 7) is a reason for caution against disregarding low-level HBsAgonly positivity as being nonspecific. Those infected with the variant virus test positive for HBsAg, and HBsAg positivity is not accompanied by the presence of anti-HBc; according to one report, most of those infected have normal transaminases and a low titer of HBsAg activity, with 97% losing HBsAg subsequently (7).
In conclusion, our observations confirm those of Skume and Garland (6) and emphasize, as recommended by the manufacturer, that all reactive specimens should be retested and repeatably reactive samples should be confirmed when the Auszyme Monoclonal test is used to detect HBsAg. Our results also emphasize the importance of patient history and follow-up laboratory tests in the accurate interpretation of test results when discrepancies are encountered.
